Novavax (NVAX) Short term Debt (2012 - 2013)

Novavax (NVAX) recorded quarterly Short term Debt of $267000.0 in Q1 2013, little changed quarter-over-quarter from $267000.0 in Q4 2012.

Novavax (NVAX) Short term Debt (2012 - 2013) Analysis & Trends

Novavax's Short term Debt history runs 2 years deep, the most recent figure standing at $267000.0 for Q1 2013.

In Q1 2013, Short term Debt changed N/A year-over-year to $267000.0; the TTM figure through Mar 2013 stood at $267000.0 (changed N/A YoY), while the FY2012 annual figure was $267000.0, changed N/A from the prior year.
Short term Debt was $267000.0 for Q1 2013 at Novavax, roughly flat from $267000.0 in the prior quarter.
In the past five years, Short term Debt ranged from a high of $769000.0 in Q3 2012 to a low of $267000.0 in Q4 2012.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Novavax	1.49 Bn	931.98 Mn	108.82 Mn

Download Data